Table 1.
CRION | RION | MS-ON | P-value (Mann-Whitney U test) | ||
---|---|---|---|---|---|
CRION vs. RION | CRION vs. MS-ON | ||||
n | 7 | 11 | 13 | ||
Sex F:M | 5:2 | 6:5 | 11:2 | 0.4* | 0.4* |
Age of onset (y) | |||||
Mean ±SD (min–max) | 29.8 ± 13.7 (20.3–55.6) | 30.2 ± 13.9 (7.6–56) | 30.9 ± 5.4 (24–39) | 0.9 | 0.4 |
Disease duration (y) | |||||
Mean ± SD | 8.5 ± 6.1 | 10.4 ± 7.2 | 12 ± 4 | 0.5 | 0.2 |
Median (range) | 6.70 (1.6–17.3) | 9.3 (4.3–30.4) | 10.3 (7.5–20.2) | ||
Time to recurrence (m) | |||||
Median (range) | 9 (2–81.3) | 14 (1.25–98.8) | 11 (1.7–231) | 0.9 | 0.7 |
Number of ON attacks/patient | |||||
Mean ± SD | 4.4 ± 3.4 | 3.1 ± 2.2 | 1.8 ± 0.7 | 0.5 | 0.046 |
Median (range) | 4 (1–11) | 2 (1–9) | 2 (1–3) | ||
Simultaneous bilateral ON attacks; n patients (%) | 6 (85.7) | 5 (45.5) | 2 (15.3) | 0.1* | 0.004* |
>1 episode of ON n (%) | 6 (85.7) | 11 (100) | 9 (69) | 0.4* | 0.4* |
Steroid dependency; n (%) | 7 (100) | 0 | 0 | 0.000* | 0.000* |
VA after the first episode | |||||
Mean ± SD | 0.4 ± 0.2 | 0.6 ± 0.2 | 0.7 ± 0.3 | 0.069 | 0.000 |
Median (range) | 0.5 (0.1–0.6) | 0.6 (0.3–0.8) | 0.7 (0.3–1) | ||
VA at last follow-up | |||||
Mean ± SD | 0.5 ± 0.2 | 0.8 ± 0.1 | 0.9 ± 0.1 | 0.003 | 0.000 |
Median (range) | 0.5 (0.1–0.7) | 0.8 (0.6–1) | 1 (0.6–1) | ||
Last EDSS | |||||
Mean ± SD | 2 ± 0.8 | 1 ± 0.7 | 2.6 ± 1.5 | 0.035 | 0.4 |
Median (range) | 2 (1–3) | 1 (0–2) | 2.5 (0–5.5) | ||
OCB IgG; n (%) | 1 (14.3) | 1 (9.1) | 12 (92.3) | 0.6* | 0.001* |
MOG-Ab+; n (%) | 4 (57.1) | 1 (9.1) | 0 | 0.047* | 0.007* |
AQP4-Ab+; n (%) | 0 | 0 | 0 | NA | NA |
Abnormal orbital MRI; n (%) | 4 (57.1) | 0 | 0 | 0.011* | 0.007* |
Abnormal brain MRI; n (%) | 0 | 2 (18.2) | 13 (100) | 0.4* | 0.000* |
Abnormal spinal MRI; n (%) | 0 | 2 (18.2) | 6 (46.2) | 0.4* | 0.022* |
Number of treatments; n | |||||
Mean ± SD | 2.2 ± 1.1 | 0.5 ± 0.9 | 2 ± 1.4 | 0.003 | 0.6 |
Median (range) | 2 (1–4) | 0 (0–3) | 2 (1–4) | ||
Treatment; n patients (%) | 4 (57.1) | 2 (18.2) | 9 (69.2) | 0.1* | 0.4* |
Last treatment (n, %) | |||||
None | 3 (42.9) | 9 (81.8) | 1 (7.7) | ||
AZA | 1 (9.1) | ||||
MFM | 1 (14.2) | ||||
RTX | 3 (42.8) | 1 (9.1) | |||
Any DMT | 12 (92.3) |
Fisher exact test.
n, number; SD, standard deviation; F, female; M, male; y, years; m, months; ON, optic neuritis; BON, bilateral optic neuritis; VA, visual acuity; EDSS, Expanded Disability Status Scale; OCB, oligoclonal bands; AQP4-Ab, aquaporin-4 antibody; MOG-Ab, myelin oligodendrocyte glycoprotein antibody; AZA, azathioprine; MFM, mycophenolate mofetil; RTX, rituximab; IVIG, intravenous immunoglobulins; DMT, disease-modifying treatment; NA, not applicable. Values in bold when p < 0.05.